• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

People with type 2 diabetes and chronic kidney disease have a high risk for kidney failure
and cardiovascular (CV) complications. Glucagon-like peptide-1 receptor agonists and …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

The American College of Cardiology (ACC) has a long history of develo** documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …

Background Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has
favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 …

Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under
development for the treatment of type 2 diabetes (T2D) and obesity. Its association with …